# 2026-07422: FDA Sets Review Period for UNLOXCYT Patent Extension

2026-07422, Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-16, effective 2026-04-16; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-07422
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-07422
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 20467
- Published: 2026-04-16
- Effective: 2026-04-16
- Comments close: 2026-06-15
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Sets Review Period for UNLOXCYT Patent Extension

## Summary

The FDA has set the official review period for UNLOXCYT, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind UNLOXCYT and anyone interested in patent timing or drug development. If you think the dates are wrong or want to challenge the company’s diligence, you have until mid-2026 to speak up—potentially impacting patent length and market exclusivity.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UNLOXCYT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

## Effects PRIA read

- FDA Sets 2,000-Day Review Period: benefit, medium. If you are the patent holder or work for the company behind UNLOXCYT, FDA has officially determined the regulatory review period is 2,000 days (1,289 days testing phase and 711 days approval phase). This determination establishes the maximum potential length of a patent extension; the applicant (Ch…
- Deadlines to Challenge Dates or Diligence: benefit, low. If you believe any published dates are wrong, you must submit comments asking for a redetermination by June 15, 2026. If you want FDA to decide whether the applicant acted with due diligence during the review period, you may file a petition by October 13, 2026.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-07422 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/16/2026-07422/determination-of-regulatory-review-period-for-purposes-of-patent-extension-unloxcyt)
- [2026-07422 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07422.pdf)

## Related
- [Previous: 2026-07421, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-07421)
- [Next: 2026-07423, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-07423)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-07422 (as of 2026-06-08).
